Upcoming Data Presentation on ROS1 and ALK Inhibitors at ESMO Congress 2024
Tuesday, 16 July 2024, 07:44
Nuvalent Data Presentation at ESMO Congress 2024
Exciting Updates on ROS1 and ALK Inhibitors
Nuvalent will reveal the most recent findings on their ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024. Don't miss out on the cutting-edge research and potential implications for treatment outcomes.
- New data on ROS1-Selective Inhibitor, Zidesamtinib
- Insights into ALK-Selective Inhibitor, NVL-655
- Advancements in targeted therapies
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.